Veno-occlusive disease of the liver associated with chronic myelomonocytic leukemia treated with vincristine and standard doses of cytarabine.

Abstract	A unique case of a 72-year-old man with chronic myelomonocytic leukemia (CMML) who developed hepatic veno-occlusive disease (VOD) after treatment with a single dose of vincristine and standard doses of cytarabine is described. Unexpected peroneal nerve palsy suggestive of vincristine neurotoxicity occurred concurrently and pointed to vincristine as the most likely cause of the VOD. To the best of our knowledge, association between vincristine and hepatic VOD has not been previously described in chemotherapy-naive patients with CMML.
Authors	A M Boula, E Mantadakis, I M Xilouri, A V Christoforidou, A M Foudoulakis, G Samonis
Journal	American journal of hematology (Am J Hematol) Vol. 79 Issue 3 Pg. 216-9 (Jul 2005) ISSN: 0361-8609 [Print] United States
PMID	15981233 (Publication Type: Case Reports, Journal Article)
Chemical References	Cytarabine Vincristine
Topics	Aged Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use) Cytarabine (therapeutic use) Disease Progression Fatal Outcome Hepatic Veno-Occlusive Disease (chemically induced, diagnosis) Humans Hypoalbuminemia Leukemia, Myelomonocytic, Chronic (complications, drug therapy) Male Paresis Renal Insufficiency Thrombocytopenia Vincristine (adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!